Baidu Ventures has backed the small molecule cancer therapy developer’s latest round, which came after a slew of healthtech and biotech investments made by the unit in recent months.

Baidu Ventures, a subsidiary of internet company Baidu, took part in a $75m series C round for China-based immuno-oncology therapeutics developer GenFleet Therapeutics on Friday, representing the unit’s latest biotechnology deal. Private equity firm Huagai Capital led the round, which included Suxin Venture Capital, Cherami Investment Group, ABC International, Dyee Capital, Qiaojing Eastern Investment, Wenzhou…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.